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Preparation of expression plasmids
The aprA, aprY, aprR, and aprT were amplified from the genomic DNA of A. flavus CA14 with the primer set shown in Table S1 . The two mutants aprA/Y3F and aprA/Y6F were amplified from pUC57-Km-aprA/Y3F and pUC57-Km-aprA/Y6F that are synthesized by GENEWIZ, respectively (see also page S17 for each sequence). Expression plasmids were constructed as follows. Gene aprA, aprA/Y3F, and aprA/Y6F were inserted into the NheI site of pUSA2 1 using an In-Fusion® HD Cloning Kit (Clontech Laboratories) to construct pUSA2-aprA. Similary, gene aprY was cloned into the KpnI site of pUARA2 1 to five pUARA2-aprY. Genes aprR and aprT were cloned NheI and/or KpnI sites of pAdeA2 2 to construct three plasmids, pAdeA2-aprR, pAdeA2-aprT, and pAdeA2-aprRT. These procedures are summarized in Figure S1 .
Transformation of A. oryzae.
Transformation of A. oryzae was performed by the protoplast-polyethylene glycol method reported previlusly 3 to construct the following transformants; AO-aprYRT, AO-aprAYR, AO-aprART, AOaprAYRT, AO-bscAYRT/Y3F, and AO-aprAYRT/Y6F,. Plasmids used for the construction of each transformant are summarized in Table S2 .
Extraction of the metabolites from each transformant
Mycelia of A. oryzae transformants were inoculated into 20 mL of potato-starch medium (potato infusion from 200 g and 20 g soluble starch for 1 L medium). Each culture was incubated at 30°C, 200 rpm for 3 days. After the fermentation, broth was extracted by 80 mL acetone. After centrifugation, the supernatants were concentrated to give the crude extract. 5-l Aliquots of each extract were analyzed by LC-MS with Acquity UPLC BEH C18 column (2.1 x 50 mm, 1.7 m) at the following conditions; CH3CN and H2O (each contained 0.1% HCOOH) were used as eluents. The concentration of CH3CN was linearly increased from 5 to 50% over 2 min, 50 to 95% over 1 min. Flow rate was kept at 0.7 ml min -1 . The column temperature was kept at 40˚C. Metabolites were analyzed in ESI positive mode.
Isolation of 1 from A. oryzae transformant AO-aprAYRT
Spore suspension of AO-aprAYRT was inoculated into 100 mL of potato-maltose medium (potato infusion from 200g and 30 g maltose for 1L medium) in 500 mL Erlenmeyer flasks. Each culture was incubated at 30˚C for 6 days. After filtration, broth was collected and was washed with AcOEt, and then extracted by n-butanol. Organic layer was subjected to C18 column chromatography (eluted by CH3CN/H2O = 0.1-0.3). The fraction containing asperipin-2a was separated by HPLC (Shimazu Class VP system) equipped with Wakopak Navi C18-5 column (10 x 250 mm, 5 m). MeOH and H2O (each contained 0.1% RFA) were used as eluents. The concentration of MeOH was linearly increased from 25% to 75% over 10min. Flow rate was kept at 3 mL min -1 . After several injections, the fractions containing the pure compound was collected (1.0 mg from 400-mL culture).. 
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Hydrogenolysis and hydrolysis of 1.
A mixture of 10% Pd/C (1.7 mg), ammonium formate (0.5 g, 7.9 mmol) and 1 (0.34 mg, 0.42 mol) in MeOH (1 ml) was stirred at 70˚C until reaction was completed. 4 The mixture was filtrated through
Celite. The filtrate was purified by C18 column chromatography and HPLC equipped with Wakopak Navi C18-5 (10 x 250 mm) at the conditions (a linear gradient of MeOH from 25-40% over 25min
at a flow rate of 3.0 mL min -1 ). To solution of the linear peptide (3% MeOH, 500 l) was added 12 M HCl solution (500 l) and stirred at 110˚C for 13 h.
Chiral separation of (S)-and (R)-3-phenyllactic acid
The resulting 3-phenyllactic acid was analyzed by LC-MS equipped with chiral column (CHIRALPAK®ZWIX(+), 4 x 250 mm, 3 m) at the conditions (isocratic elution by 10 mM HCO2H and 10 mM HCO2NH4 in MeOH/H2O (98/2, v/v) at a flow rate of 0.8 ml min -1 ). Commercial S-and R-3-phenyllactic acid were used as references. An ACQUITY QDa MS detector was operated in ESInegative mode.
Derivatization of the resultant amino acids with Marfey's reagent.
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